Pharmacogenetics to Avoid Adverse Drug Reactions

Adverse drug reactions are one of the major constraints when using drugs. These adverse reactions can impact healthcare systems as strongly as many prevalent diseases. Identifying DNA variants associated with adverse drug reactions can help personalize medicine and sustain healthcare systems. This b...

Full description

Saved in:
Bibliographic Details
Sonstige:
Year of Publication:2022
Language:English
Physical Description:1 electronic resource (220 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 03221nam-a2200925z--4500
001 993546039004498
005 20231214133507.0
006 m o d
007 cr|mn|---annan
008 202203s2022 xx |||||o ||| 0|eng d
035 |a (CKB)5400000000045301 
035 |a (oapen)https://directory.doabooks.org/handle/20.500.12854/79654 
035 |a (EXLCZ)995400000000045301 
041 0 |a eng 
100 1 |a López-Fernández, Luis A.  |4 edt 
245 1 0 |a Pharmacogenetics to Avoid Adverse Drug Reactions 
260 |a Basel  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2022 
300 |a 1 electronic resource (220 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
520 |a Adverse drug reactions are one of the major constraints when using drugs. These adverse reactions can impact healthcare systems as strongly as many prevalent diseases. Identifying DNA variants associated with adverse drug reactions can help personalize medicine and sustain healthcare systems. This book delves into new advances in pharmacogenetics of cardiovascular, cancer, and nervous system drugs. It may be useful for clinicians and patients to understand the basics of pharmacogenetics. 
546 |a English 
650 7 |a Medicine  |2 bicssc 
653 |a 5-fluorouracil 
653 |a capecitabine 
653 |a fluoropyrimidine 
653 |a thymidylate synthase 
653 |a thymidylate synthase enhancer region 
653 |a upstream stimulatory factor 1 
653 |a adverse drug reactions 
653 |a pharmacogenomics 
653 |a epistasis 
653 |a random forest 
653 |a statin 
653 |a cardiovascular disease 
653 |a colorectal cancer 
653 |a personalised medicine 
653 |a toxicity 
653 |a (es)citalopram 
653 |a drug-gene-interaction 
653 |a drug-drug-interaction 
653 |a drug-drug-gene-interaction 
653 |a the PharmLines initiative 
653 |a antipsychotic agents 
653 |a pharmacogenetics 
653 |a cytochrome P-450 enzyme system 
653 |a psychotic disorders 
653 |a precision medicine 
653 |a direct oral anticoagulants 
653 |a clinical implementation 
653 |a atorvastatin 
653 |a SLCO1B1 
653 |a HLA 
653 |a cutaneous adverse drug reaction 
653 |a SCAR 
653 |a genetic polymorphism 
653 |a antiepileptics 
653 |a CYP450 enzymes 
653 |a platelet reactivity 
653 |a single-nucleotide variants 
653 |a acute coronary syndrome 
653 |a clopidogrel 
653 |a genotype 
653 |a allele 
653 |a polymorphism 
653 |a HLA B 
653 |a CYP2C9*3 
653 |a cutaneous adverse drug reactions (CADRs) 
653 |a anti-epileptic drugs (AEDS) 
653 |a phenytoin (PHT) 
653 |a genetic risk factors 
653 |a South India 
653 |a India 
653 |a cardiology 
653 |a adverse events 
653 |a guidelines 
776 |z 3-0365-3344-3 
776 |z 3-0365-3343-5 
700 1 |a López-Fernández, Luis A.  |4 oth 
906 |a BOOK 
ADM |b 2023-12-15 05:55:50 Europe/Vienna  |f system  |c marc21  |a 2022-04-04 09:22:53 Europe/Vienna  |g false 
AVE |i DOAB Directory of Open Access Books  |P DOAB Directory of Open Access Books  |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338144260004498&Force_direct=true  |Z 5338144260004498  |b Available  |8 5338144260004498